Immunotherapy-chemotherapy combination extends survival in … – Healio
|
Immunotherapy-chemotherapy combination extends survival in …
Healio CHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to … |
